Učitavanje...
KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
Significant challenges to develop selective and effective pharmacological inhibitors for important oncoproteins like RAS continue impeding the success to treat cancers driven by such mutations. In the present study, the ABT263 and axitinib combination imposed synergistic effects on RAS-mutant colon...
Spremljeno u:
| Izdano u: | Biosci Rep |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Portland Press Ltd.
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6400663/ https://ncbi.nlm.nih.gov/pubmed/30674639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BSR20181786 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|